Voyager Therapeutics, Inc. announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc. Dr. Colón most recently served as President, CEO and Director of InCarda Therapeutics, Inc., where she led the company's growth from seed stage to late-clinical stage and oversaw strategy, commercial planning and pipeline growth. Prior to InCarda, Dr. Colón served as a partner and senior advisor to New Science Ventures LLC, where she led and co-led several investments and provided strategic and operational guidance to multiple life science portfolio companies.

Previously, among multiple other roles, Dr. Colón served as a Senior Vice President and President of the Industrial Products Division at Precigen, Inc., and in various leadership roles at Gilead Sciences, Inc., including Head of Clinical Operations, Head of Alliance Management, and Head of Commercial Strategic Planning. Dr. Colón currently serves as a member of the Boards of Directors of CareDx, Inc.; the Massachusetts Institute of Technology Corporation; and the Biotechnology Innovation Organization (BIO), and she serves as the Executive Chair of ProterixBio, Inc. Previously, she served on the boards of PerceptiMed, Inc.; Paradigm Diagnostics, Inc.; and Cocoon Biotech, Inc. Dr. Colón received her Ph.D. in chemical engineering from MIT, where she was an NSF Fellow, and earned a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar. Dr. Colón's appointment to Voyager's Board of Directors will become effective on January 1, 2023.